Insight

Improving Reporting Standards in Lung Cancer Trials

Lung Cancer/X

Dec 8, 2024, 04:24

Improving Reporting Standards in Lung Cancer Trials

Aakash Desai, Assistant Professor and Associate Director at UAB O’Neal Comprehensive Cancer Center, shared an article by William J. Phillips on LinkedIn:

“Improving Reporting Standards in Lung Cancer Trials.

A recent study published in International Association for the Study of Lung Cancer journal JTO (Articles in Press, Dec 4, 2024) highlights key gaps in reporting efficacy and toxicity in early-phase lung cancer trials:

88% of studies used subjective terms like “manageable” or “tolerable” (ISJET language) to describe toxicity.
Only 12% distinguished between Grade 1 and 2 adverse events (AEs), despite the growing relevance of chronic treatments.
These findings call for more objective and transparent reporting practices to align with modern oncology care needs. Better standards can lead to clearer data interpretation, benefiting researchers, clinicians, and patients alike.

The use of investigator-assigned subjective or judgmental efficacy and toxicity reporting in early phase clinical trials of lung cancer treatments.

Authors: William J. Phillips, et al.

Improving Reporting Standards in Lung Cancer Trials

More posts featuring Aakash Desai.

Aakash Desai cancer IASLC International Association for the Study of Lung Cancer JTO Lung cancer OncoDaily Oncology UAB O'Neal Comprehensive Cancer Center William J. Phillips

New Paper Alert: Hepatocellular Carcinoma - Stereotactic Body Radiotherapy vs Sorafenib Alone in the NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial - JAMA Oncology

Vivek Subbiah: Top Phase 1 clinical trial publications of 2024

Monica Bertagnolli: 2024 Science Highlights from the NIH Director’s Blog

365 Days of OncoDaily: Ending 2024 Strong

Aladina Foundation was Honored with the Yvonne Humanitarian Award by OncoDaily

Special Coverage